| Literature DB >> 14699377 |
Joel T M Bamford1, Barbara A Elliott, Irina V Haller.
Abstract
Twenty-four patients with erythrotelangiectatic or papulopustular rosacea were treated with 0.1% tacrolimus topical ointment in a 12-week open-label trial. Erythema was significantly improved in both rosacea subtypes (P<.05). There was no decrease in the number of papulopustular lesions. Side effects were consistent with those on the tacrolimus topical ointment labeling.Entities:
Mesh：
Substances：
Year: 2004 PMID： 14699377 DOI： 10.1016/s0190-9622(03)02157-1
Source DB: PubMed Journal: J Am Acad Dermatol ISSN： 0190-9622 Impact factor: 11.527